Moneyta · stock research · no sign-up needed
PDSB
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue
—
Net income (Q2 FY2026)
-$10M
as filed with the SEC
Institutions holding
—
Overview · PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in…
Management team
- Dr. Kirk V. Shepard M.D. · Chief Medical OfficerFind on LinkedIn
- Ms. Deanne Randolph · Head of Investor RelationsFind on LinkedIn
- Mr. Lars Robert Boesgaard M.B.A. · Chief Financial OfficerFind on LinkedIn
- Mr. Sanjay Zaveri · Senior Vice President of Business DevelopmentFind on LinkedIn
Start your free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on PDSB
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
7-day free trial. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data — insight, not advice.